Update on Examinership Process
Dublin, 29 January 2024. The board of HealthBeacon plc ("HealthBeacon" or the "Company) announces an update on the Examinership process the Company is currently going through.
The Examiner held meetings of all members and creditors of the Company on Wednesday 24 January 2024 for the purpose of considering and voting on a Scheme of Arrangement to allow the Company survive as a going concern. All 5 classes of creditors voted to approve the scheme. The meeting of the members voted to reject the proposals, although a majority in number but not value voted for the scheme.
The Examiner has now presented his report to the High Court under section 534 of the Companies Act 2014 and it is anticipated that the hearing seeking sanction from the High Court of the Scheme of Arrangement will be heard by the end of next week following which the Company will make a further announcement.
-Ends-
| Enquiries: |
|
| HealthBeacon: Rebecca Shanahan Lar Malone
|
|
| Goodbody (Euronext Listing Sponsor and Broker): Finbarr Griffin
|
+353 (1) 667 0420 |
| |
|
| Drury (Public Relations): |
|
| Cathal Barry |
+353 (0) 87 227 9281 |
| Gavin McLoughlin |
+353 (0) 86 035 3749 |
About HealthBeacon
Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company that develops smart tools for managing medications for patients in the home. The HealthBeacon Injection Care Management System tracks adherence and persistence with medication schedules through the provision of medication management reminders, safe and sustainable sharps disposal devices, educational tools, and artificial intelligence (AI) driven data analytics. Peer reviewed evidence supports a 19% improvement in therapy persistence by patients and up to 26% improvement in adherence to therapy, which improves clinical outcomes and significantly improves efficiency in health systems. The Company has expanded its offering to growth management with the launch of its integrated Smart Scale and oral adherence with the launch of HB Wave which integrates with its existing technology. The Company operates across Europe, North America and the United Kingdom and employs more than 70 people and has obtained more than 30 design and utility patents. The Company's mission is to become the world's leading digital therapeutics platform for patients managing medications in the home.
End
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.